Showing results (291-300 of 308) with videos related to
Sort By:
Pageof 31
Neuro-Oncology|November 11, 2020
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I studySolmaz Sahebjam, Peter A Forsyth, Nam D Tran, et al.Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.International Journal of Radiation Oncology, Biology, Physics|April 7, 2020
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424Barbara J Fisher, Stephanie L Pugh, David R Macdonald, et al.JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.Medrxiv : the Preprint Server for Health Sciences|May 15, 2024
Intricacies of Human-AI Interaction in Dynamic Decision-Making for Precision Oncology: A Case Study in Response-Adaptive RadiotherapyDipesh Niraula, Kyle C Cuneo, Ivo D Dinov, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancerDonald A Podoloff, Ranjana H Advani, Craig Allred, et al.JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.Nature Communications|January 29, 2025
Intricacies of human-AI interaction in dynamic decision-making for precision oncologyDipesh Niraula, Kyle C Cuneo, Ivo D Dinov, et al.NPJ Breast Cancer|November 21, 2024
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastasesVaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda, et al.The Journal of Clinical Investigation|February 2, 2022
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistanceJia Zou, Li Li, Peiyi Zheng, et al.Pageof 31